[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
3. Shimizu Y, Komiyama S, Kobayashi T, Nakata K, Iida T: Successful management of endodermal sinus tumor of the ovary associated with pregnancy. Gynecol Oncol; 2003 Mar;88(3):447-50
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful management of endodermal sinus tumor of the ovary associated with pregnancy.
  • BACKGROUND: Pregnancy complicated by endodermal sinus tumor of the ovary has rarely been reported.
  • CASE: A 32-year-old pregnant woman was found to have an ovarian tumor.
  • At 19 weeks of gestation, tumorectomy was performed and a diagnosis of primary endodermal sinus tumor of the ovary (stage Ic) was made.
  • Pregnancy was continued without postoperative chemotherapy.
  • Subsequently, three courses of combination chemotherapy with bleomycin, etoposide, and cisplatin were administered.
  • There was no evidence of recurrence at 27 months after initial treatment.
  • CONCLUSIONS: Successful management of endodermal sinus tumor of the ovary in a pregnant woman is reported.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endodermal Sinus Tumor / drug therapy. Ovarian Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12648602.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Kang H, Kim TJ, Kim WY, Choi CH, Lee JW, Kim BG, Bae DS: Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol; 2008 Oct;111(1):106-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
  • OBJECTIVE: The aim of this study was to investigate the outcome and reproductive function of patients with ovarian endodermal sinus tumor (EST) after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP).
  • METHODS: Between 1995 and 2006, 1034 patients with the diagnosis of ovarian cancer were treated at a single institution.
  • Among these patients, 51 had a confirmed diagnosis of malignant ovarian germ cell tumor (MOGCT) including 20 cases of EST.
  • We retrospectively reviewed those patients with EST, who received BEP as adjuvant chemotherapy.
  • Of the 15 patients who were treated with fertility-sparing surgery, all had regular menstruation following the completion of adjuvant chemotherapy, and two of these patients had pregnancies with live birth deliveries and no complications.
  • CONCLUSION: In patients with EST, the cumulative high-dose BEP regimen resulted in excellent overall survival and did not seem to impair ovarian function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / physiopathology. Fertility. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / physiopathology. Ovary / physiopathology
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Bleomycin / adverse effects. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Gynecologic Surgical Procedures / methods. Humans. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656249.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


5. Thanaboonyawat I, Benjapibal M: A case of ovarian endodermal sinus tumor diagnosed during pregnancy. J Med Assoc Thai; 2008 May;91(5):764-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endodermal sinus tumor diagnosed during pregnancy.
  • Pregnancy complicated by endodermal sinus tumor of the ovary is extremely rare.
  • The authors present a case report of a pregnant woman with persistent left adnexal mass and subsequently found to have a primary endodermal sinus tumor of the ovary that was diagnosed at 19 weeks of gestation.
  • After left salpingo-oophorectomy had been performed, the patient chose to terminate the pregnancy before the initiation of combination chemotherapy with bleomycin, etoposide, and cisplatin.
  • The response to chemotherapy was not satisfactory.
  • The patient expired after seven cycles of treatment had been completed because of pulmonary fibrosis and the drug toxicity of bleomycin.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Abortion, Induced. Adult. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / adverse effects. Antineoplastic Agents, Phytogenic / therapeutic use. Bleomycin / adverse effects. Bleomycin / therapeutic use. Cisplatin / adverse effects. Cisplatin / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Fatal Outcome. Female. Humans. Ovariectomy / methods. Pregnancy. Pregnancy Trimester, First. Pulmonary Fibrosis / chemically induced

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672645.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. de La Motte Rouge T, Pautier P, Duvillard P, Rey A, Morice P, Haie-Meder C, Kerbrat P, Culine S, Troalen F, Lhommé C: Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. Ann Oncol; 2008 Aug;19(8):1435-41
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor.
  • BACKGROUND: Ovarian yolk sac tumor (YST) is a very rare malignancy arising in young women.
  • Chemotherapy has dramatically improved the prognosis.
  • Current treatment consists of surgery followed by bleomycin, etoposide, and cisplatin (BEP) chemotherapy.
  • However, given the rarity of this tumor, ovarian YST-specific survival and outcome after such treatment are not precisely known.
  • PATIENTS AND METHODS: This report concerns prospectively recorded cases that were either treated at Institut Gustave Roussy (Villejuif, France) or referred there for advice about therapy.
  • From 1990 to 2006, 52 patients underwent surgery followed by BEP chemotherapy.
  • Data on patient characteristics, treatment, survival, and fertility outcome were analyzed to assess treatment efficacy and gonadal toxicity after achieving a complete remission.
  • With a median follow-up of 68 months, the overall 5-year survival and disease-free survival rates were 94% and 90%, respectively.
  • CONCLUSIONS: BEP chemotherapy following fertility-sparing surgery is a very effective treatment of ovarian YSTs.

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408223.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Aoki Y, Higashino M, Ishii S, Tanaka K: Yolk sac tumor of the ovary during pregnancy: a case report. Gynecol Oncol; 2005 Nov;99(2):497-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yolk sac tumor of the ovary during pregnancy: a case report.
  • BACKGROUND: There is a therapeutic dilemma for the pregnant patient with malignancy requiring chemotherapy.
  • CASE: We had a case of a 30-year-old pregnant woman with a yolk sac tumor who underwent right salpingo-oophorectomy at 22 weeks gestation.
  • Chemotherapy during pregnancy was postponed because of concern with the risks of the chemotherapy to the fetus.
  • Tumor recurrence was confirmed clinically at 34 weeks gestation.
  • She was induced, delivering a healthy baby, and received seven complete chemotherapy courses (cisplatin, etoposide, and peplomycin).
  • Currently, the mother (39 months after last chemotherapy) and child are doing well.
  • CONCLUSION: AFP-L2 may be a sensitive indicator for a yolk sac tumor derived AFP, leading to an earlier detection of tumor recurrence during pregnancy.
  • [MeSH-major] Endodermal Sinus Tumor. Ovarian Neoplasms. Pregnancy Complications, Neoplastic
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Peplomycin / administration & dosage. Plant Lectins. Pregnancy. alpha-Fetoproteins / metabolism


8. Motegi M, Takakura S, Takano H, Tanaka T, Ochiai K: Adjuvant chemotherapy in a pregnant woman with endodermal sinus tumor of the ovary. Obstet Gynecol; 2007 Feb;109(2 Pt2):537-40
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy in a pregnant woman with endodermal sinus tumor of the ovary.
  • BACKGROUND: The administration of chemotherapeutic drugs during pregnancy is rare.
  • We describe a case of malignant ovarian tumor complicating pregnancy.
  • A normal infant was delivered, and no evidence of tumor recurrence was observed.
  • There was no evidence of recurrence observed at 65 months after the initial treatment.
  • CONCLUSION: Although the risk of chemotherapy to the fetus cannot be assessed based on a single case, this experience is encouraging.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Ovarian Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Prenatal Diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cesarean Section. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Infant, Newborn. Pregnancy. Pregnancy Trimester, Third. Prenatal Care. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Prenatal Testing.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267887.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 25
  •  go-up   go-down


9. Benjapibal M, Chaopotong P, Leelaphatanadit C, Jaishuen A: Ruptured ovarian endodermal sinus tumor diagnosed during pregnancy: case report and review of the literature. J Obstet Gynaecol Res; 2010 Oct;36(5):1137-41
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for ovarian endodermal sinus tumor .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ruptured ovarian endodermal sinus tumor diagnosed during pregnancy: case report and review of the literature.
  • Pregnancy complicated by endodermal sinus tumor of the ovary is a very rare event.
  • We present a case report of a pregnant woman with a ruptured primary endodermal sinus tumor of the ovary that was diagnosed at 13 weeks of gestation.
  • After right salpingo-oophorectomy had been performed the patient received four cycles of combination chemotherapy (bleomycin, etoposide, and cisplatin) starting at the 15th week of pregnancy.
  • The patient did not have any evidence of tumor recurrence for 23 months.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Ovarian Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Female. Humans. Ovariectomy. Pregnancy. Rupture, Spontaneous / diagnosis. Rupture, Spontaneous / drug therapy. Rupture, Spontaneous / surgery. Treatment Outcome


10. Manchana T, Sirisabya N, Lertkhachonsuk R, Tresukosol D: Transient cortical blindness during chemotherapy (PVB) for ovarian germ cell tumor. J Med Assoc Thai; 2006 Aug;89(8):1265-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient cortical blindness during chemotherapy (PVB) for ovarian germ cell tumor.
  • A 17 year-old female with stage IIIc endodermal sinus tumor of the ovary developed transient cortical blindness and severe hypertension after 5 cycles of PVB regimen consisting of cisplatin, vinblastine and bleomycin.
  • Her visual acuity and blood pressure completely recovered within a few days after supportive treatment with antihypertensive drug.
  • Most reports suggested that this rare toxicity was from cisplatin therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bleomycin / adverse effects. Blindness, Cortical / chemically induced. Brain Diseases / chemically induced. Brain Diseases / pathology. Cisplatin / administration & dosage. Cisplatin / adverse effects. Endodermal Sinus Tumor / drug therapy. Ovarian Neoplasms / drug therapy. Vinblastine / administration & dosage. Vinblastine / adverse effects
  • [MeSH-minor] Adolescent. Female. Humans. Magnetic Resonance Imaging. Neoplasm Staging


11. Cyganek A, Ejmocka-Ambroziak A, Wiczyńska-Zajac A, Marianowski L: [Ovarian endodermal sinus tumor associated with pregnancy--a case report]. Ginekol Pol; 2002 Apr;73(4):408-11
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian endodermal sinus tumor associated with pregnancy--a case report].
  • An ovarian endodermal sinus tumor was found in a 29-years old patient with a 32-week intrauterine gestation.
  • She received caesarean section, conservative surgery and three courses of combination chemotherapy.
  • She died 6 months after the diagnosis.
  • [MeSH-major] Endodermal Sinus Tumor. Ovarian Neoplasms. Pregnancy Complications, Neoplastic
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Female. Humans. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12152296.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


12. Jeyakumar A, Chalas E, Hindenburg A: Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor. Gynecol Oncol; 2001 Sep;82(3):578-80
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor.
  • BACKGROUND: Yolk sac tumors of the ovary are generally very responsive to chemotherapy; however, they are difficult to manage in the setting of platinum resistance where treatment options are limited and outcomes are poorer.
  • CASE: We present a 39-year-old woman who had a platinum-resistant yolk sac ovarian tumor.
  • CONCLUSION: The combination of docetaxel, gemcitabine, and thalidomide might be an active regimen for platinum-resistant ovarian nondysgerminomas and further investigation of this combination is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endodermal Sinus Tumor / drug therapy. Ovarian Neoplasms / drug therapy. Taxoids
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Female. Humans. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Thalidomide / administration & dosage

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11520160.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 4Z8R6ORS6L / Thalidomide; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Kamoi S, Ohaki Y, Mori O, Okada S, Seto M, Matsushita N, Kawamura T, Araki T: A case of ovarian endometrioid adenocarcinoma with yolk sac tumor component in a postmenopausal woman. APMIS; 2002 Jun;110(6):508-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endometrioid adenocarcinoma with yolk sac tumor component in a postmenopausal woman.
  • The co-existence of an endometrioid adenocarcinoma with an ovarian yolk sac tumor is very rare.
  • A 54-year-old postmenopausal woman with a 6-month history of progressive abdominal distension was seen at our hospital.
  • MR imaging revealed a large cyst with a solid intramural node.
  • At laparotomy, a large tumor approximately 20 cm in diameter was found to occupy the abdominal cavity, adhering to the swollen appendix and part of the omentum.
  • Microscopically, foci of endometrioid adenocarcinoma together with a yolk sac tumor component were observed within a large endometriotic cyst.
  • Since the tumor was clinically staged 1c, the patient was given 500 mg of intraperitoneal carboplatin postoperatively, followed by five courses of combination chemotherapy consisting of cisplatin, etoposide and peplomycin at 4-week intervals.
  • In contrast to a very poor prognosis of this tumor in previously reported cases, our patient showed no sign of recurrence during a 21-month follow-up period.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endodermal Sinus Tumor / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antigens, Tumor-Associated, Carbohydrate / analysis. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Middle Aged. Postmenopause. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12193212.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


14. Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, Sokal M, Gray E, McKeever P, Hale J, Bailey S, Oakhill A: The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol; 2000 Nov 15;18(22):3809-18
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.
  • PURPOSE: To evaluate carboplatin, etoposide, and bleomycin (JEB) in children with malignant extracranial germ cell tumors (GCTs).
  • PATIENTS AND METHODS: Malignant GCTs in children aged 0 to 16 years were excised without major morbidity or otherwise biopsied.
  • Stage I testicular and some ovarian GCTs were resected and monitored with alpha-fetoprotein (AFP) ("watch-and-wait" approach).
  • Chemotherapy toxicities were assessed using World Health Organization or Brock grading.
  • Eight were excluded because either there was no histologic diagnosis (n = 3) or chemotherapy was given off-study (n = 5).
  • The remaining 184 patients had germinoma (n = 20), malignant teratoma (n = 55), embryonal carcinoma (n = 1), yolk sac tumor (n = 107), or choriocarcinoma (n = 1).
  • The median follow-up after JEB treatment was 53 months (range, 0 to 109 months); the median number of courses was five (range, three to eight).
  • One child died of a thoracic tumor and bronchopulmonary dysplasia, and another died of acute myeloid leukemia.
  • CONCLUSION: Conservative surgery, a watch-and-wait approach after complete excision, and JEB for those requiring chemotherapy produced high cure rates and few serious complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Ovarian Neoplasms / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Bleomycin / administration & dosage. Bleomycin / adverse effects. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Chorionic Gonadotropin / blood. Combined Modality Therapy. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Infant. Infant, Newborn. Male. Prognosis. Survival Analysis. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11078494.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; JEB protocol
  •  go-up   go-down


15. Schmidt D, Kommoss F: [Teratoma of the ovary. Clinical and pathological differences between mature and immature teratomas]. Pathologe; 2007 May;28(3):203-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Teratoma of the ovary. Clinical and pathological differences between mature and immature teratomas].
  • [Transliterated title] Teratome des Ovars. Klinisch-pathologische Unterschiede zwischen unreifen und reifen Teratomen.
  • Teratomas are the most frequent germ cell tumors of the ovary.
  • Mature teratomas are benign tumors, which are most often composed of derivatives of two or three germ cell layers.
  • Only in rare cases is the transition into a malignant tumor observed (most often squamous cell carcinoma).
  • In contrast, immature teratomas are malignant ovarian tumors.
  • They contain immature tissue elements in addition to the mature components, most often consisting of immature neural tissue.
  • Histologically, this tumor component can be identified as neurotubules or rosettes.
  • The proportion of immature tissue elements defines the grade of immaturity.
  • With the exception of childhood cases, grade 2 and 3 immature teratomas are treated with chemotherapy.
  • In childhood cases, foci of yolk sac tumor (YST) must be looked for, since this determines the prognosis.
  • If a focus of YST is present, the patient is treated with chemotherapy.
  • In cases of immature peritoneal implants, patients are also treated with chemotherapy.
  • Gliomatosis peritonei is most likely derived from metaplasia of subperitoneal stem cells; it does not represent a metastatic disease of the ovarian teratoma.
  • [MeSH-major] Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Neuroblastoma / pathology. Prognosis

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1978 Aug;102(8):420-5 [580884.001]
  • [Cites] Pathol Res Pract. 1989 Apr;184(4):422-30 [2726609.001]
  • [Cites] N Engl J Med. 1975 Jan 9;292(2):63-6 [162806.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):685-8 [15188134.001]
  • [Cites] Mod Pathol. 2006 Jun;19(6):766-71 [16547466.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):597-601 [9195578.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1115-24 [9737245.001]
  • [Cites] Am J Surg Pathol. 1993 Aug;17(8):764-78 [8393302.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):296-302 [17080330.001]
  • [Cites] J Clin Pathol. 1983 Jan;36(1):68-73 [6822679.001]
  • [Cites] Int J Oncol. 2004 Jul;25(1):17-25 [15201985.001]
  • [Cites] Int J Gynecol Pathol. 2005 Apr;24(2):173-82 [15782074.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):263-71 [10811491.001]
  • [Cites] Am J Obstet Gynecol. 1946 Feb;51:151-72 [21012750.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S61-79 [15761467.001]
  • [Cites] APMIS. 2003 Jan;111(1):152-60; discussion 160 [12752256.001]
  • [Cites] Am J Obstet Gynecol. 1999 Aug;181(2):353-8 [10454682.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):82-5 [11781530.001]
  • [Cites] Cancer. 1976 May;37(5):2359-72 [1260722.001]
  • (PMID = 17396268.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Zhao S, Kato N, Endoh Y, Jin Z, Ajioka Y, Motoyama T: Ovarian gonadoblastoma with mixed germ cell tumor in a woman with 46, XX karyotype and successful pregnancies. Pathol Int; 2000 Apr;50(4):332-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian gonadoblastoma with mixed germ cell tumor in a woman with 46, XX karyotype and successful pregnancies.
  • An extremely rare case of unilateral gonadoblastoma with mixed germ cell tumor arising in the ovary of a 27-year-old woman with 46,XX karyotype and two successful pregnancies is reported.
  • The mixed germ cell tumor was composed of choriocarcinoma, embryonal carcinoma, yolk sac tumor, immature teratoma and dysgerminoma.
  • The patient has been well, without evidence of disease for over 10 years since her first surgery and adjuvant chemotherapy.
  • [MeSH-major] Germinoma. Gonadoblastoma. Ovarian Neoplasms

  • Genetic Alliance. consumer health - Ovarian germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10849320.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  •  go-up   go-down


17. Erdemoglu E, Ozen S: Ovarian gonodoblastoma with yolk sac tumor in a young 46, XX female: case report. Eur J Gynaecol Oncol; 2007;28(6):516-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian gonodoblastoma with yolk sac tumor in a young 46, XX female: case report.
  • BACKGROUND: Gonodoblastomas with ovarian germ cell tumors (OGCTs) other than dysgerminoma are very unusual.
  • This is the first case report of a pure endodermal sinus tumor of the ovary with gonodoblastoma in a 46 XX, female.
  • Fertility sparing surgery was undertaken and revealed a Stage IA endodermal sinus tumor and gonodoblastoma in the same ovary.
  • The patient refused chemotherapy and was followed-up for six months without disease.
  • Tumor markers and immunohistochemical examination may help in the diagnosis of these OGCTs with gonodoblastoma.
  • [MeSH-major] Endodermal Sinus Tumor / genetics. Gonadoblastoma / genetics. Ovarian Neoplasms / genetics

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179152.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


18. Ohishi Y, Kaku T, Kaneki E, Wake N, Tsuneyoshi M: Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study. Gynecol Oncol; 2007 May;105(2):548-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study.
  • BACKGROUND: Cases of malignant ovarian tumor composed of müllerian-type epithelial tumor and malignant germ cell tumor are extremely rare.
  • CASE: We herein report the case of a 34-year-old woman with an ovarian tumor which was composed of endometrioid adenocarcinoma (EAC), clear cell adenocarcinoma (CCC), squamous cell carcinoma, yolk sac tumor (YST) and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation.
  • Even after systemic chemotherapy, this intriguing tumor recurred again and again, which is in contrast to pure germ cell tumor which is known to be sensitive to chemotherapy.
  • Correct diagnosis of this complex and aggressive tumor is paramount.
  • [MeSH-major] Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adult. Carcinoma, Endometrioid / pathology. Carcinoma, Squamous Cell / pathology. Endodermal Sinus Tumor / pathology. Female. Humans. Neuroectodermal Tumors / pathology. Rhabdomyosarcoma / pathology. Teratoma / pathology


19. De Backer A, Madern GC, Oosterhuis JW, Hakvoort-Cammel FG, Hazebroek FW: Ovarian germ cell tumors in children: a clinical study of 66 patients. Pediatr Blood Cancer; 2006 Apr;46(4):459-64
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian germ cell tumors in children: a clinical study of 66 patients.
  • BACKGROUND: Ovarian germ cell tumors are rare in childhood.
  • The aim of this study is to review clinical presentation, management, and outcome in a two-center series of girls with ovarian germ cell tumor.
  • PROCEDURE: The records of 66 patients (median age 9 years) with histologically proven ovarian germ cell tumor (either benign or malignant), treated over a 44-year-span, were reviewed.
  • Sixteen patients had an emergency operation for tumor torsion.
  • Unilateral salpingo-oophorectomy was the most frequently performed procedure (n = 46), and ovarian-sparing tumorectomy was performed in 9 patients (one bilaterally).
  • Histologically, teratomas were found most frequently (mature: 45, immature: 9), followed by mixed tumors (n = 7), yolk sac tumors (n = 3), dysgerminoma (n = 2), gonadoblastoma (n = 2), and embryonal carcinoma (n = 1).
  • Surgical removal of the tumor with or without the ovary and/or adnex was the sole treatment in 55 patients, chemotherapy was administered in 10 and radiotherapy + chemotherapy in one.
  • Two patients, with malignant disease, died.
  • The 64 survivors are now between 8 months and 44 years after treatment.
  • CONCLUSIONS: With a recurrence rate of 4.5% and a mortality rate of 3%, this series confirms the excellent prognosis for girls with ovarian germ cell tumor (GCT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206211.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


20. Ayhan A, Taskiran C, Bozdag G, Altinbas S, Altinbas A, Yuce K: Endodermal sinus tumor of the ovary: the Hacettepe University experience. Eur J Obstet Gynecol Reprod Biol; 2005 Dec 1;123(2):230-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endodermal sinus tumor of the ovary: the Hacettepe University experience.
  • OBJECTIVE: The purpose of this study was to evaluate the treatment regimens used for patients with endodermal sinus tumors (EST), and also to examine the prognostic value of surgicopathological variables.
  • STUDY DESIGN: Twenty-two patients treated for pure EST, and seven patients who had mixed germ cell tumors with EST components were included.
  • Initial surgery consisting of surgical staging to achieve optimal debulking was the principal mode of therapy.
  • RESULTS: The median age at the time of diagnosis was 18 (range 8-45).
  • As an adjuvant therapy 18 patients (62%) received platin-based chemotherapy, three patients (10%) had non-platin-based chemotherapy, four patients (14%) had radiotherapy, and four patients (14%) had combined radiotherapy plus non-platin-based chemotherapy.
  • Platin-based chemotherapy achieved significant survival benefit (P = 0.03 and P < 0.001, respectively).
  • There was no significant survival difference with respect to age, histology, and tumor size.
  • CONCLUSION: Fertility-sparing surgery with a postoperative platin-based combination chemotherapy should be the selected mode of treatment.
  • [MeSH-major] Endodermal Sinus Tumor / therapy. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Female. Gynecologic Surgical Procedures. Hospitals, University. Humans. Middle Aged. Neoplasm Staging. Platinum Compounds / therapeutic use. Prognosis. Retrospective Studies. Survival Analysis. Turkey

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026921.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds
  •  go-up   go-down


21. Zuntová A, Sumerauer D, Teslík L, Kabícková E, Koutecký J: [Mixed germ cell tumours of the ovary in childhood and adolescence]. Cesk Patol; 2004 Jul;40(3):92-101
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed germ cell tumours of the ovary in childhood and adolescence].
  • [Transliterated title] Smísené germinální nádory ovaria u dĕtí a dospívajících. Retrospektivní klinicko-patologická studie.
  • Mixed germ cell tumours of the ovary are rare malignant neoplasms containing combinations of two or more types of germ cell elements.
  • The aim of the study was to review biopsy examinations, medical records, treatment strategy, follow-up and outcome of all girls treated for mixed germ cell tumour of the ovary at the Department of Pediatric Oncology, University Hospital Motol during the period 1979-2002.
  • The clinical data on surgical treatment, chemotherapy and radiotherapy used and follow-up information were obtained in all girls.
  • Sixteen girls with mixed germ cell tumour of the ovary, age range 3 years 11 months to 17 years 8 months (median 12 years) were treated.
  • All girls presented with unilateral tumour of the ovary and all underwent surgery as an initial treatment.
  • The original diagnosis of mixed histology was confirmed in all cases; in five cases the tumour contained three histologic components, in eleven cases the tumour consisted of two germ cell types.
  • All tumours contained elements of yolk sac tumour, followed by immature teratoma, embryonal carcinoma, dysgerminoma and mature teratoma.
  • At the time of diagnosis three patients had stage I disease, four patients stage II, seven stage III and two stage IV disease.
  • All patients were treated with chemotherapy after surgery, predominantly with platinum-based regimens (PVB, BEP).
  • Overall survival and event-free survival were 80% and 81.3% respectively (median follow-up time 7.6 years).
  • Three patients have died from the disease, two progressed on treatment (MAC), one girl relapsed three months after finishing therapy, no further therapy was administered.
  • One girl underwent resection of tumour of her remaining ovary 24 months after original diagnosis.
  • Microscopic examination should be extensive and careful to find out all types of malignant germ cell elements.
  • Platinum based chemotherapy is effective in the management of children and adolescents with mixed germ cell tumors of the ovary.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493415.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


22. Rzepka-Górska I, Błogowska A, Zajaczek S, Zielińska D: [Germinal cell tumors in young and adolescent girls]. Ginekol Pol; 2003 Sep;74(9):840-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Germinal cell tumors in young and adolescent girls].
  • OBJECTIVE: Germ cell tumours are the most common ovarian tumours in childhood and adolescence.
  • This diverse group of tumours derives from germ cells.
  • DESIGN: The aim of this work is presentation of germ cell tumours in the material from our clinic with characteristic clinical features, the scope of operation and effects of many years of observation.
  • MATERIALS AND METHODS: We treated 109 girls with germ cell tumours of the ovary: 13 had malignant tumours: there were 7 patients with dysgerminomas, 2 with endodermal sinus tumour of the ovary, 3 with immature teratomas, 1 with carcinoma embryonale.
  • There can be problems with diagnosis of the syndrome, because developmental features imitate the onset of normal puberty.
  • It must be suggested that patients of stage I who wish to preserve childbearing function may be treated with unilateral salpingoophorectomy and adjuvant chemotherapy.
  • Monitoring of the treatment is connected with measurement of biochemical markers.
  • Some of these markers are useful for monitoring of response to therapy.
  • Cytological smears and biopsy specimens from the remaining ovary, peritoneum and subdiaphragmatic area should be obtained laparoscopically.
  • CONCLUSIONS: The sift ultrasonographic investigations can be helpful in the early diagnosis of germ cell tumours of the ovary in girls.
  • Fertility sparing operative treatment is preferred when karyotype is normal.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / blood. Child. Combined Modality Therapy. Dysgerminoma / pathology. Dysgerminoma / therapy. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Female. Germinoma / pathology. Germinoma / therapy. Gonadoblastoma / pathology. Gonadoblastoma / therapy. Gonadotropins / blood. Gonadotropins / genetics. Humans. Poland. Risk Factors. Teratoma / pathology. Teratoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14674134.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gonadotropins
  •  go-up   go-down


23. Lopez JM, Malpica A, Deavers MT, Ayala AG: Ovarian yolk sac tumor associated with endometrioid carcinoma and mucinous cystadenoma of the ovary. Ann Diagn Pathol; 2003 Oct;7(5):300-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian yolk sac tumor associated with endometrioid carcinoma and mucinous cystadenoma of the ovary.
  • The clinicopathologic and immunohistochemical findings of an unusual case of ovarian yolk sac tumor associated with endometrioid carcinoma and mucinous cystadenoma of the ovary are reported.
  • The tumor was detected in a 51-year-old postmenopausal woman who presented with abdominal swelling and a pelvic mass.
  • The tumor was confined to the right ovary and measured 16.0 cm in greatest dimension.
  • Microscopic examination revealed that the tumor had a yolk sac component associated with an endometrioid carcinoma, grade I, and a mucinous cystadenoma.
  • Immunoperoxidase studies showed that the yolk sac component stained diffusely with a cytokeratin cocktail and was focally positive for alpha-fetoprotein.
  • In contrast, the endometrioid carcinoma stained positive for keratin 7 in addition to the cytokeratin cocktail, but was negative for alpha-fetoprotein.
  • After surgery, the patient received three cycles of chemotherapy.
  • However, the disease progressed and the patient died 10 months after the diagnosis of the ovarian tumor.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenoma, Mucinous / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Gynecologic Surgical Procedures. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasms, Multiple Primary. Postmenopause

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14571433.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 17
  •  go-up   go-down


24. Abe A, Furumoto H, Yoshida K, Nishimura M, Irahara M, Kudo E, Sano T: A case of ovarian endometrioid adenocarcinoma with a yolk sac tumor component. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):168-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endometrioid adenocarcinoma with a yolk sac tumor component.
  • Endometrioid adenocarcinoma of the ovary coexists very rarely with yolk sac tumor (YST).
  • This unusual mixed tumor is thought to be a rare variant of endometrioid ovarian carcinoma because of its aggressive behavior, lack of response to chemotherapy, and unfavorable prognosis.
  • We report a case of ovarian endometrioid adenocarcinoma with a YST component in a postmenopausal woman.
  • She has been clinically free of tumor for 20 months.
  • The occurrence of this unusual case suggests that even somatic carcinomas may acquire an extraembryonal germ cell differentiation.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bridged Compounds / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Immunoenzyme Techniques. Middle Aged. Platinum / administration & dosage. Taxoids / administration & dosage. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466041.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 1605-68-1 / taxane; 49DFR088MY / Platinum; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Moodley M, Moodley J: Ovarian germ cell malignancy and human immunodeficiency virus (HIV) infection: a case report. Int J Gynecol Cancer; 2003 Jul-Aug;13(4):541-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian germ cell malignancy and human immunodeficiency virus (HIV) infection: a case report.
  • The occurrence of germ cell tumors in patients with human immunodeficiency virus (HIV) infection has not been previously reported.
  • The approach to management as well as the role of adjuvant radiotherapy and chemotherapy is problematic as many of these therapies are toxic.
  • The presentation, management, and outcome of ovarian endodermal sinus tumor in a HIV-infected patient is reported.
  • [MeSH-major] Germinoma / complications. Germinoma / therapy. HIV Infections / complications. Ovarian Neoplasms / complications. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Ovariectomy / methods. Radiotherapy, Adjuvant. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12911735.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Hong DG, Chong GO, Seong WJ, Lee YS, Cho YL, Park JY, Chae JM, Park IS: A case of ovarian endometrioid adenocarcinoma with yolk sac tumor in a 35-year-old woman. Eur J Gynaecol Oncol; 2010;31(4):471-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endometrioid adenocarcinoma with yolk sac tumor in a 35-year-old woman.
  • Ovarian yolk sac tumor (YST) is a malignant ovarian neoplasm differentiated from primordial germ cells that occur in young age, while endometrioid carcinoma (ECA) is a müllerian epithelial tumor that usually occurs in older patients.
  • The coexistence of an ovarian ECA and YST component is very rare.
  • We present a case of a simultaneous ECA and a YST component in a 35-year-old woman.
  • After completion of four courses of BEP chemotherapy, two courses of taxane and carboplatin chemotherapy were added.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882900.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


27. Mikuz G: [WHO classification of testicular tumors]. Verh Dtsch Ges Pathol; 2002;86:67-75
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] WHO-Klassifikation der Hodentumoren.
  • The most important is obviously the precursor lesion of germ cell tumors, which has been called "intratubular malignant germ cells".
  • Such atypical cells appear in the tubules adjacent to the germ cell tumors, in some few cases (6%) also in the contra lateral healthy gonad and rarely in infertile men (1%).
  • The precursor lesion can progress to franc germ cell tumor starting probably with seminoma, which still maintain the capability of differentiation (pluripotente cells) in all other types of non-seminomatous germ cell tumors.
  • This lesion is missed in germ cell tumors of childhood and in spermatocytic seminomas, both seem to have a histogenetic history rather different from the other germ cell in adults.
  • Unfortunately, however, the old term "teratoma with malignant transformation" was changed to "teratoma with malignant areas" in the 1998 classification.
  • This is a harmless name for an extremely dangerous tumor in which one tissue overgrows the other and gives rise to somatic type sarcomas or carcinomas.
  • Such tumors do not respond like germ cell tumors to the usual chemotherapy.
  • Treatment should be tailored according to that used in standard management of the respective sarcoma or carcinoma.
  • In the comments it is mentioned that the testis carcinoid could be a part of teratoma, but the diagnosis is listed in the group of "miscellaneous" tumors together with tumors of ovarian epithelial type.
  • This is a very questionable decision because the normal testis does not contain neuroendocrine cells from which carcinoids would have to be able to develop.
  • "Large cell calcifying Sertoli cell tumour" has been recently described and can be sporadic or inherited.
  • This morphologically peculiar tumor can be part of the Swiss syndrome also called Carney's complex.
  • The patients have cardiac myxomas, spotty skin pigmentation, hormone active nodular hyperplasia of the adrenals and soft tissue myxomas.
  • The newly appearing "mixed germ cell--sex cord/gonadal stromal tumours, unclassified" has a histology similar to the well known gonadoblastomas.
  • For the therapy of germ cell tumor an assessment of risk factors found by the pathologists is extremely important.
  • The most important independent predictors of relapse are tumor invasion of blood or lymph-vessels, absence of yolk sac elements and the presence of an embryonal carcinoma component.
  • In the absence of such predictors a surveillance policy allows some patients to forgo chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12647353.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


28. Ali L, Bambach BJ, Kozielski R, Wagner H, Lele S, Mhawech-Fauceglia P: Ovarian yolk sac tumor associated with major fibrosarcoma component in a 13-year-old girl. Int J Gynecol Pathol; 2010 May;29(3):252-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian yolk sac tumor associated with major fibrosarcoma component in a 13-year-old girl.
  • We are presenting a case of a 13-year-old girl with a chief complaint of lower abdominal pain.
  • A computed tomographic scan showed a 10-cm right ovarian mass.
  • The final diagnosis was a yolk sac tumor with a major (95%) fibrosarcoma component, based on morphology and further confirmed by an extensive panel of immunohistochemistry.
  • The patient completed 7 cycles of multiagent chemotherapy with cisplatin without major complications.
  • To our knowledge, our case is the first of its kind in the literature to document yolk sac tumor associated with fibrosarcoma in a teenage female.
  • [MeSH-major] Endodermal Sinus Tumor / pathology. Fibrosarcoma / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407325.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


29. Ratnapala SR, Ratnapala SD: Pregnancy after excision of a yolk sac tumour of the ovary followed by chemotherapy. Ceylon Med J; 2004 Dec;49(4):134-5
MedlinePlus Health Information. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy after excision of a yolk sac tumour of the ovary followed by chemotherapy.
  • [MeSH-major] Dysgerminoma / diagnosis. Dysgerminoma / therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / therapy. Pregnancy. Pregnancy Outcome. Pregnancy, High-Risk. Yolk Sac / pathology
  • [MeSH-minor] Adult. Cesarean Section. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Ovariectomy / methods. Risk Assessment






Advertisement